The Molecular Tumor Board of the Regina Elena National Cancer Institute: from accrual to treatment in real-world.

Patrizio GiacominiFabio ValentiMatteo AllegrettiMatteo PalloccaFrancesca De NicolaLudovica CiuffredaMaurizio FanciulliStefano ScaleraSimonetta BuglioniElisa MelucciBeatrice CasiniMariantonia CarosiEdoardo PescarmonaElena GiordaniFrancesca SperatiNicoletta JannittiMartina BettiMarcello Maugeri-SaccàFabiana Letizia CecereVeronica VillaniAndrea PaceMarialuisa AppetecchiaPatrizia ViciAntonella SavareseEriseld KrasniqiVirginia FerraresiMichelangelo RussilloAlessandra FabiLorenza LandiGabriele MinutiFederico CappuzzoMassimo ZeuliGennaro Ciliberto

Published in: Journal of translational medicine (2023)

MTB-recommended/non-SoC treatments are effective, including those assigned by ctDNA-only alterations. However, real-world MTBs may inadvertently recruit patients electively susceptible to diverse and/or multiple treatments.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
mycobacterium tuberculosis
prognostic factors
patient reported outcomes
circulating tumor
patient reported
cell free